CoALL07- 03 high- risk- standard:
I: Induction, vincristine (4x 1,5 mg/m²) / daunorubicine (3x 36 mg/m²) / methylprednisolone (60 mg/m²/d for 28 days); C1a: cyclophosphamide (900 mg/m2) / methotrexate (1 g/m2) / E.coli asparaginase (45000 IE/m2)/ methotrexate intrathecal (age-dependent dose); C1b: cyclophosphamide (900 mg/m2) / methotrexate (1 g/m2) / E.coli asparaginase (45000 IE/m2) / 6-mercaptopurine (100 mg/m2/d for 7 days) / methotrexate intrathecal (age-dependent dose); C2a: methotrexate (1 g/m2) / teniposide (VM26) (165 mg/m2) / cytarabine (300 mg/m2) / 6-mercaptopurine (100 mg/m2/d for 7 days) / methotrexate intrathecal (age-dependent dose); C2b: methotrexate (1 g/m2) /teniposide (VM26) (165 mg/m2) / cytarabine (300 mg/m2) / 6-thioguanine (100 mg/m2/d for 7 days) / methotrexate intrathecal (age-dependent dose); C3a: high- dose cytarabine (4x3 g/m2) / pegylated asparaginase (2500 IE/m2); CNS- phase: methotrexate intrathecal (3x age-dependent dose) / CNS- radiotherapy when indicated / 6-mercaptopurine (50 mg/m2/d for 28 days); delayed intensification: vincristine (4x 1,5 mg/m²) / doxorubicine (4x 30 mg/m²) / pegylated asparaginase (2x 2500 IE/m2) / cyclophosphamide (2x 900 mg/m2) / cytarabine (8x 90 mg/m²) / methotrexate intrathecal (3x age-dependent dose) / dexamethasone (2x 10 mg/m²/d for 14 days) / 6-thioguanine (2x 100 mg/m2/d for 7 days); maintenance: 6-mercaptopurine (daily per os, dose dependent on leukocyte count) / methotrexate (weekly per os, dose dependent on leukocyte count) / methotrexate intrathecal (3x age-dependent dose)